The 36-month beta value for SCLX is also noteworthy at 1.17. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SCLX is 5.11M, and at present, short sellers hold a 7.07% of that float. The average trading volume of SCLX on June 12, 2025 was 121.96K shares.
SCLX) stock’s latest price update
The stock price of Scilex Holding Company (NASDAQ: SCLX) has plunged by -7.30 when compared to previous closing price of 6.03, but the company has seen a -19.80% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-05 that PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal.
SCLX’s Market Performance
Scilex Holding Company (SCLX) has seen a -19.80% fall in stock performance for the week, with a 36.34% gain in the past month and a -48.78% plunge in the past quarter. The volatility ratio for the week is 2.62%, and the volatility levels for the past 30 days are at 8.50% for SCLX. The simple moving average for the past 20 days is 6.21% for SCLX’s stock, with a -69.04% simple moving average for the past 200 days.
Analysts’ Opinion of SCLX
Many brokerage firms have already submitted their reports for SCLX stocks, with D. Boral Capital repeating the rating for SCLX by listing it as a “Buy.” The predicted price for SCLX in the upcoming period, according to D. Boral Capital is $22 based on the research report published on January 27, 2025 of the current year 2025.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see SCLX reach a price target of $14. The rating they have provided for SCLX stocks is “Buy” according to the report published on October 16th, 2024.
Rodman & Renshaw gave a rating of “Buy” to SCLX, setting the target price at $13 in the report published on June 13th of the previous year.
SCLX Trading at -3.02% from the 50-Day Moving Average
After a stumble in the market that brought SCLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.06% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at SCLX starting from SHAH JAISIM, who purchase 30,000 shares at the price of $0.46 back on Dec 18 ’24. After this action, SHAH JAISIM now owns 139,333 shares of Scilex Holding Company, valued at $13,800 using the latest closing price.
Ji Henry, the Executive Chairperson of Scilex Holding Company, purchase 8,888 shares at $0.94 during a trade that took place back on Oct 31 ’24, which means that Ji Henry is holding 320,161 shares at $8,351 based on the most recent closing price.
Stock Fundamentals for SCLX
Current profitability levels for the company are sitting at:
- -1.81 for the present operating margin
- 0.72 for the gross margin
The net margin for Scilex Holding Company stands at -1.47. The total capital return value is set at 0.47.
Based on Scilex Holding Company (SCLX), the company’s capital structure generated -0.24 points at debt to capital in total, while cash flow to debt ratio is standing at 0.38. The debt to equity ratio resting at -0.2. The interest coverage ratio of the stock is -23.46.
Currently, EBITDA for the company is -66.8 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 1.47. The receivables turnover for the company is 4.78for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.
Conclusion
In summary, Scilex Holding Company (SCLX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
